Fig. 5From: Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysisCorrelation between response and immune-related adverse events by system organ class in nivolumab plus ipilimumabBack to article page